ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

AMAM Ambrx Biopharma Inc

28,00
0,00 (0,00%)
21 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Ambrx Biopharma Inc AMAM NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
0,00 0,00% 28,00 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
28,00 28,00
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
18/3/202419:45EDGAR2Form 15-12G - Securities registration termination [Section..
12/3/202421:55EDGAR2Form 8-K - Current report
11/3/202405:15EDGAR2Form EFFECT - Notice of Effectiveness
08/3/202419:39EDGAR2Form S-8 POS - Securities to be offered to employees in..
07/3/202419:23EDGAR2Form POS AM - Post-Effective amendments for registration..
07/3/202414:49EDGAR2Form 8-K - Current report
06/3/202422:05EDGAR2Form 8-K - Current report
23/2/202420:09EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
22/2/202414:31EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
22/2/202414:30EDGAR2Form 8-K - Current report
12/2/202419:43PRNUSKuehn Law Encourages AMAM, DOOR, CBAY, and WISH Investors to..
10/1/202421:07PRNUSKuehn Law Encourages AMAM, HARP, AXNX, and CPE Investors to..
08/1/202420:54DJNTrending: Johnson & Johnson and Merck & Co. Announce..
08/1/202416:04DJNAmbrx Biopharma Shares Double on $2 Billion Acquisition by..
08/1/202414:12DJNJohnson & Johnson to Acquire Cancer-Treatment Developer..
23/10/202323:19EDGAR2Form 15-12G - Securities registration termination [Section..
15/9/202322:27EDGAR2Form DEFM14A - Definitive proxy statement relating to merger..
15/9/202322:24EDGAR2Form 8-K - Current report
06/9/202322:05EDGAR2Form 8-K - Current report
25/8/202323:23EDGAR2Form 8-K - Current report
19/7/202315:49DJNAmbrx Biopharma Gets Fast Track Designation for ARX517..
28/6/202322:45EDGAR2Form SC 13D/A - General statement of acquisition of..
28/6/202322:06EDGAR2Form 8-K - Current report